Patents by Inventor Marinus Jacobus Verwijs

Marinus Jacobus Verwijs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CRYSTALLINE COMPOUNDS AND METHODS OF MAKING THE SAME
    Publication number: 20240166636
    Abstract: Provided herein are methods for making a crystalline form of N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide hydrobromide and related products, compositions and treatment methods.
    Type: Application
    Filed: September 21, 2023
    Publication date: May 23, 2024
    Inventors: Marinus Jacobus VERWIJS, David Jon AM ENDE, Stephen Richard ANDERSON, Andrew Paul George BEEVERS, Mark Kenneth BREAULT, Stephen Richard TUDHOPE, Jamie Ross WOLSTENHULME
  • PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR MEDIATED DISEASES
    Publication number: 20230364073
    Abstract: Pharmaceutical compositions comprising 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1) in Form I and a solid dispersion comprising substantially amorphous N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (Compound 2), methods of treating, lessening the severity of, or symptomatically treating CFTR mediated diseases, such as cystic fibrosis, methods of manufacturing, methods of administering, and kits thereof are disclosed.
    Type: Application
    Filed: December 30, 2022
    Publication date: November 16, 2023
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Marinus Jacobus VERWIJS, Radhika KARKARE, Michael Douglas MOORE
  • PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF
    Publication number: 20230210839
    Abstract: The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.
    Type: Application
    Filed: December 30, 2022
    Publication date: July 6, 2023
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: William Rowe, Patricia Hurter, Christopher Young, Kirk Dinehart, Marinus Jacobus Verwijs, Kirk Overhoff, Peter D.J. Grootenhuis, Martyn Botfield, Alfredo Grossi
  • Pharmaceutical composition and administrations thereof
    Patent number: 11564916
    Abstract: The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: January 31, 2023
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: William Rowe, Patricia Hurter, Christopher Young, Kirk Dinehart, Marinus Jacobus Verwijs, Kirk Overhoff, Peter D. J. Grootenhuis, Martyn Botfield, Alfredo Grossi
  • FORMULATIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID
    Publication number: 20220354797
    Abstract: A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a disintegrant, a surfactant, a binder, and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Processes of preparing pharmaceutical compositions comprising Compound 1 are also disclosed.
    Type: Application
    Filed: February 12, 2021
    Publication date: November 10, 2022
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventor: Marinus Jacobus Verwijs
  • PHARMACEUTICAL COMPOSITIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL) BENZOIC ACID AND ADMINISTRATION THEREOF
    Publication number: 20220031679
    Abstract: A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient.
    Type: Application
    Filed: May 28, 2021
    Publication date: February 3, 2022
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Marinus Jacobus VERWIJS, Rossitza Gueorguieva ALARGOVA, Ritu Rohit KAUSHIK, Irina Nikolaevna KADIYALA, Christopher YOUNG
  • CRYSTALLINE COMPOUNDS AND METHODS OF MAKING THE SAME
    Publication number: 20210221800
    Abstract: Provided herein are methods for making a crystalline form of N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide hydrobromide and related products, compositions and treatment methods.
    Type: Application
    Filed: April 1, 2021
    Publication date: July 22, 2021
    Inventors: Marinus Jacobus VERWIJS, David Jon AM ENDE, Stephen Richard ANDERSON, Andrew Paul George BEEVERS, Mark Kenneth BREAULT, Stephen Richard TUDHOPE, Jamie Ross WOLSTENHULME
  • Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof
    Patent number: 11052075
    Abstract: A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo [d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: July 6, 2021
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Marinus Jacobus Verwijs, Rossitza Gueorguieva Alargova, Ritu Rohit Kaushik, Irina Nikolaevna Kadiyala, Christopher Young
  • PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF
    Publication number: 20210023070
    Abstract: The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.
    Type: Application
    Filed: April 7, 2020
    Publication date: January 28, 2021
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: William Rowe, Patricia Hurter, Christopher Young, Kirk Dinehart, Marinus Jacobus Verwijs, Kirk Overhoff, Peter D.J. Grootenhuis, Martyn Botfield, Alfredo Grossi
  • PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR MEDIATED DISEASES
    Publication number: 20200338063
    Abstract: Pharmaceutical compositions comprising 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1) in Form I and a solid dispersion comprising substantially amorphous N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (Compound 2), methods of treating, lessening the severity of, or symptomatically treating CFTR mediated diseases, such as cystic fibrosis, methods of manufacturing, methods of administering, and kits thereof are disclosed.
    Type: Application
    Filed: December 20, 2019
    Publication date: October 29, 2020
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Marinus Jacobus VERWIJS, Radhika KARKARE, Michael Douglas MOORE
  • PHARMACEUTICAL COMPOSITIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL) BENZOIC ACID AND ADMINISTRATION THEREOF
    Publication number: 20200197380
    Abstract: A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo [d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient.
    Type: Application
    Filed: August 2, 2019
    Publication date: June 25, 2020
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Marinus Jacobus Verwijs, Rossitza Gueorguieva Alargova, Ritu Rohit Kaushik, Irina Nikolaevna Kadiyala, Christopher Young
  • Pharmaceutical composition and administrations thereof
    Patent number: 10646481
    Abstract: The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: May 12, 2020
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: William Rowe, Patricia Hurter, Christopher Young, Kirk Dinehart, Marinus Jacobus Verwijs, Kirk Overhoff, Peter D. J. Grootenhuis, Martyn Botfield, Alfredo Grossi
  • FORMULATIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID
    Publication number: 20200085750
    Abstract: A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a disintegrant, a surfactant, a binder, and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Processes of preparing pharmaceutical compositions comprising Compound 1 are also disclosed.
    Type: Application
    Filed: July 26, 2019
    Publication date: March 19, 2020
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventor: Marinus Jacobus Verwijs
  • PHARMACEUTICAL COMPOSITIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL) BENZOIC ACID AND ADMINISTRATION THEREOF
    Publication number: 20190070155
    Abstract: A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient.
    Type: Application
    Filed: July 31, 2018
    Publication date: March 7, 2019
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Marinus Jacobus VERWIJS, Rossitza Gueorguieva ALARGOVA, Ritu Rohit KAUSHIK, Irina Nikolaevna KADIYALA, Christopher YOUNG
  • Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof
    Patent number: 10076513
    Abstract: A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: September 18, 2018
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Marinus Jacobus Verwijs, Rossitza Gueorguieva Alargova, Ritu Rohit Kaushik, Irina Nikolaevna Kadiyala, Christopher Young
  • FORMULATIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID
    Publication number: 20180008546
    Abstract: A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a disintegrant, a surfactant, a binder, and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Processes of preparing pharmaceutical compositions comprising Compound 1 are also disclosed.
    Type: Application
    Filed: July 20, 2017
    Publication date: January 11, 2018
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventor: Marinus Jacobus Verwijs
  • PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF
    Publication number: 20170087144
    Abstract: The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.
    Type: Application
    Filed: August 31, 2016
    Publication date: March 30, 2017
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: WIlliam ROWE, Patricia HURTER, Christopher YOUNG, Kirk DINEHART, Marinus Jacobus VERWIJS, Kirk OVERHOFF, Peter D.J. GROOTENHUIS, Martyn BOTFIELD, Alfredo GROSSI
  • Pharmaceutical Compositions for the Treatment of CFTR Mediated Diseases
    Publication number: 20160324846
    Abstract: Pharmaceutical compositions comprising 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1) in Form I and a solid dispersion comprising substantially amorphous N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (Compound 2), methods of treating, lessening the severity of, or symptomatically treating CFTR mediated diseases, such as cystic fibrosis, methods of manufacturing, methods of administering, and kits thereof are disclosed.
    Type: Application
    Filed: May 11, 2016
    Publication date: November 10, 2016
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Marinus Jacobus Verwijs, Radhika Karkare, Michael Douglas Moore
  • FORMULATIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID
    Publication number: 20160324788
    Abstract: A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a disintegrant, a surfactant, a binder, and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Processes of preparing pharmaceutical compositions comprising Compound 1 are also disclosed.
    Type: Application
    Filed: April 7, 2016
    Publication date: November 10, 2016
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventor: Marinus Jacobus Verwijs
  • PHARMACEUTICAL COMPOSITIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL) BENZOIC ACID AND ADMINISTRATION THEREOF.
    Publication number: 20160303096
    Abstract: A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient.
    Type: Application
    Filed: January 19, 2016
    Publication date: October 20, 2016
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: MARINUS JACOBUS VERWIJS, ROSSITZA GUEORGUIEVA ALARGOVA, RITU ROHIT KAUSHIK, IRINA NIKOLAEVNA KADIYALA, CHRISTOPHER YOUNG